In this interview, Dr. Peter McCullough discusses the importance of early treatment for COVID-19, and the potential motivations behind the suppression of safe and effective treatments.
McCullough has impeccable academic credentials. He’s an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master’s degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals.
Early Outpatient Treatment Is Key for Positive Outcomes
McCullough has been an outspoken advocate for early treatment for COVID. In August 2020, McCullough’s landmark paper “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 Infection”1 was published online in the American Journal of Medicine.
The follow-up paper is titled “Multifaceted Highly Targeted Sequential Multidrug Treatment of Early Ambulatory High-Risk SARS-CoV-2 Infection (COVID-19)”2 and was published in Reviews in Cardiovascular Medicine in December 2020.
Perhaps one of the greatest crimes in this whole pandemic is the refusal by reigning heath authorities to issue early treatment guidance. Instead, they’ve done everything possible to suppress remedies shown to work, whether it be corticosteroids, hydroxychloroquine (HCQ) with zinc, ivermectin, vitamin D or NAC.
Patients were simply told to stay home and do nothing. Once the infection had worsened to the point of near-death, patients were told to go to the hospital where most were routinely placed on mechanical ventilation — a practice that was quickly discovered to be lethal. Many doctors also seemingly panicked and refused to see patients with COVID symptoms.
“I’m glad that I personally always treated all my patients,” he says. “I wasn’t going to have the virus slaughter one of my senior citizens. And it is, I think, terrible that none of our major academic institutions innovated with a single protocol. To my knowledge, not a single major academic medical center, as an institution, attempted even to treat patients with COVID-19.
But I did use my publication power, and my editorial authority, and my position in internal medicine and some specialty medicine to publish the breakthrough paper called ‘The Pathophysiological Basis and Rationale for Early Ambulatory Treatment of COVID-19’ in the American Journal of Medicine.
It was an international effort, both community physicians and academic physicians. And to this day, that is the most frequently downloaded paper in the American Journal of Medicine.”
Early Treatment Guidelines Have Saved Millions of Lives
In December 2020, McCullough published an updated protocol, co-written with 56 other authors who also had extensive experience with treating COVID-19 outpatients. The article, “Multifaceted Highly Targeted Sequential Multidrug Treatment of Early Ambulatory High-Risk SARS-CoV-2 Infection,”3was published in the journal Reviews in Cardiovascular Medicine, of which McCullough is the editor-in-chief.
“That paper, today … is the most frequently downloaded paper from BET Journal,” McCullough says. “It also is the basis for the American Association of Physician and Surgeons COVID early treatment guide.4
We have evidence that the treatment guide has been downloaded and utilized millions of times. And it was part of the early huge kick that we had in ambulatory treatment at home towards the end of December into January, which basically crushed the U.S. curve.
We were on schedule to have 1.7 to 2.1 million fatalities in the United States, as estimated by the CDC and others. We cut it off at about 600,000. That still is a tragedy. I’ve testified that 85% of that 600,000 could have been saved if we would have had … the protocols in place from the start.
But suffice it to say, the early treatment heroes, and you’re part of that team Dr. Mercola, has really made the biggest impact. We have saved millions of lives, spared millions and millions of hospitalizations, and in a sense, have brought the pandemic now to a winnowing close.”
While the World Health Organization and national health agencies have all rejected treatments suggested by doctors for lack of large-scale randomized controlled studies, McCullough and other doctors working the frontlines took an empiric approach. They looked for signals of benefit in the literature.
“We didn’t demand large randomized trials because we knew they weren’t going to be available for years in the future,” McCullough says. “We didn’t wait for a guidelines body to tell us what to do or some medical society, because we know they work in slow motion. We knew we had to take care of patients now.”